Improved Local Control and Disease-Free Survival after Perioperative Chemotherapy for Early-Stage Breast Cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 745-753

  Clahsen, Pieter C ^b   Van De Velde, Cornelis J H ^a   Julien, Jean Pierre ^b   Floiras, Jean Louis ^b   Delozier, Thierry ^b   Mignolet, Françoise Y ^b   Sahmoud, Tarek M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EUROPE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE;

EID: 0029868439     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.745     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Fisher B, Slack N, Katrych D, et al: Ten-year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528-534, 1975
3. Nissen-Meyer R, Kjellgren K, Malmio K, et al: Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088-2098, 1978
4. Kjellgren K, Nissen-Meyer R, Norin T: Perioperative adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 1. Acta Oncol 28:899-901, 1989
5. Moore GE, Sanberg AA, Schulbarg JR: Clinical and experimental observations of the occurrence and fate of tumor cells in the blood stream. Ann Surg 146:580-587, 1957
6. Watne AI, Roberts SS, McGrew E, et al: The occurrence of cancer cells in the circulating blood and their response to surgery and chemotherapy. Int J Cancer 16:790, 1960
7. Consensus Development Conference: Treatment of primary breast cancer. Br Med J 293:946-947, 1986
8. Salsbury AJ: The significance of the circulating cancer cell. Cancer Treat Rev 2:55-72, 1975
9. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861-3865, 1979
10. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983
11. Fisher B, Gunduz N, Coyle J, et al: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49:1996-2001, 1989
12. Van Dierendonck JH: Cell kinetic aspects of breast cancer. Doctoral Thesis, Leiden, The Netherlands, 1990
13. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499, 1971
14. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
15. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643-3653, 1984
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
17. Clahsen PC, van de Velde CJH, Julien J-P, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer. A European Organization for Research and Treatment Breast Cancer Cooperative Group study. J Clin Oncol 12:1266-1271, 1994
18. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histological nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772, 1981
19. EORTC Breast Cancer Cooperative Group Manual for Clinical Research in Breast Cancer. Leuven, Belgium, EORTC: Monograph, 1991
20. Ludwig Breast Cancer Study Group: Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 2:542-544, 1983
21. Goldhirsch A, Gelber RD, Tattersall MNH, et al: Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet 2:151, 1987 (letter)
22. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
24. Cox DR: Regression models and life-tables. J R Stat Assoc B 34:187-220, 1972
25. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266:93-98, 1991
26. Baum M, Houghton J, Riley D: Results of the Cancer Research Campaign adjuvant trial for perioperative cyclophosphamide and long-term tamoxifen in early breast cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group. Acta Oncol 31:251-257, 1992
27. Nissen-Meyer R, Høst H, Kjellgren K: Prolonged adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 2. Acta Oncol 28:903-906, 1989
28. Ludwig Breast Cancer Study Group: Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988
29. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
30. Goldhirsch A, Castiglione M, Gelber RD: A single perioperative chemotherapy course for node-negative breast cancer: Five year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). Monogr Natl Cancer Inst 11:89-96, 1992
31. Bonadonna G: Adjuvant chemotherapy in node-negative breast cancer. NCI Consensus Conference. Eur J Cancer 26:844-845, 1990
32. Wood WC: Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 18:39-44, 1994
33. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347-354, 1991
34. Scholl SM, Asselain B, Beuzeboc P, et al: Improved survival rates following first line chemotherapy in operable breast cancer. 4 year results of a randomized trial (S6). Fourth International Congress on Anti-Cancer Chemotherapy (Neoadjuvant, Adjuvant and Experimental), Paris, France, February 2-5, 1993 (abstr)
35. Fisher B, et al: NSABP Protocol B-18.
36. Van de Velde CJH, Julien J-P, Tubiana-Hulin M, et al: Pre-operative chemotherapy in operable breast cancer (POCOB), the influence of timing FEC in relation to surgery. Ann Oncol 3:202, 1992 (abstr)